ALSO READVivimed Labs gains after subsidiary divests certain products Vivimed Labs hits roof after block deal Vivimed Labs Q4 net profit plunges 30% at Rs 13 crore Vivimed Labs spurts after unit successfully completes USFDA inspection Vivimed Labs consolidated net profit declines 29.75% in the March 2016 quarter
Secures ANDA approval for Metronidazole and ZolpidemVivimed Labs announced that its FDF manufacturing facility located in Alathur, near Chennai has had a favourable outcome post its US Food and Drug Administration (USFDA) inspection. The audit was conducted during the last week of November and concluded on 28 November 2016.
Furthermore, Vivimed obtained ANDA approval for Metronidazole and same is commercialised. During November 2016, the Company acquired ANDA of Zolpidem and the file transfer has successfully been completed. lt is expected to be commercialised by Q4 FY2O17. Vivimed is on track of its filing targets and has successfully completed 3 ANDA filings during FY2017 and expect one more filing to be completed by Q4 FY2017. These products provide vertical integration with the inhouse APls.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)